A Huge Biotech Purchase Highlights New Year's Insider BuyingInsider buying is a positive indicator of stock confidence.Recent insider transactions indicate increasing confidence in biopharmaceuticals and energy sectors.
Irish medtech firm to add 725 jobs with 300m expansionAerogen is expanding its workforce in Ireland, projecting significant growth in revenue and job creation across various sectors. Their innovative technology benefits millions globally.
USPTO Officially Withdraws Terminal Disclaimer ProposalUSPTO has withdrawn a proposed rule that could have imposed new limitations on terminal disclaimers, ensuring a predictable patent environment for the biopharmaceutical sector.
A Healthy Patent Family Is A Tree That Continues to Bear FruitFalse policy narratives against patents hinder innovation progress, as multiple patents are essential for complex products like biopharmaceuticals.
PhoreMost $12M Series B Financing to Advance Next-Gen Degrader ProgramsPhoreMost has raised $12 million in Series B funding, advancing its pipeline for oncology and inflammatory diseases.The company aims to move cancer treatment programs into preclinical development with this new funding.
In other news this week: Premier League footballers back Lawhive in 37.8M round, Zopa Bank secures 80M, Giant Clone launches in the Netherlands and more - Silicon CanalsZopa Bank, Antag Therapeutics, and Lawhive have all raised significant funding to launch new products and services, targeting financial health and legal accessibility.
USPTO Officially Withdraws Terminal Disclaimer ProposalUSPTO has withdrawn a proposed rule that could have imposed new limitations on terminal disclaimers, ensuring a predictable patent environment for the biopharmaceutical sector.
A Healthy Patent Family Is A Tree That Continues to Bear FruitFalse policy narratives against patents hinder innovation progress, as multiple patents are essential for complex products like biopharmaceuticals.
PhoreMost $12M Series B Financing to Advance Next-Gen Degrader ProgramsPhoreMost has raised $12 million in Series B funding, advancing its pipeline for oncology and inflammatory diseases.The company aims to move cancer treatment programs into preclinical development with this new funding.
In other news this week: Premier League footballers back Lawhive in 37.8M round, Zopa Bank secures 80M, Giant Clone launches in the Netherlands and more - Silicon CanalsZopa Bank, Antag Therapeutics, and Lawhive have all raised significant funding to launch new products and services, targeting financial health and legal accessibility.
Innovent Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug ListInnovent's SINTBILO® is officially included in the 2024 NRDL, marking a significant advancement in cholesterol management in China.
PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular DegenerationPharmAbcine is advancing monoclonal antibody therapy, significantly targeting diseases with high efficacy and low side effects.
New generation of radioactive drugs strike cancer with molecular precisionX-ray therapy initiated a revolution in cancer treatment that has evolved significantly over the years, leading to more precise and effective therapies.
In other news this week: VividQ secures 6.7M, Reliant AI bags 10.1M, in.hub raises funding, Agtech Startup of the Year, and more - Silicon CanalsVividQ raises funds to enhance immersive AR technology for various sectors.Vandria secures funding to develop treatments for age-related neurological diseases.